HeXun Biosciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	286.42	130.57	49.47	-
Revenue Growth (YoY)	119.36%	163.94%	-	-
Cost of Revenue	25.75	16.84	4.86	-
Gross Profit	260.67	113.73	44.61	-
Selling, General & Admin	39.57	33.14	14.23	5.95
Research & Development	65.37	53.22	39.36	44.71
Operating Expenses	104.94	86.36	53.59	50.66
Operating Income	155.73	27.37	-8.98	-50.66
Interest Expense	-1.18	-1.85	-1.64	-1.57
Interest & Investment Income	4.41	2.79	0.46	0.03
Currency Exchange Gain (Loss)	-0.79	0.53	0.02	-
Other Non Operating Income (Expenses)	3.3	4.7	4.93	9.01
EBT Excluding Unusual Items	161.48	33.54	-5.21	-43.19
Gain (Loss) on Sale of Assets	-0.01	-0.05	0.02	0.2
Pretax Income	161.47	33.49	-5.19	-42.99
Income Tax Expense	14.25	-	-	-
Net Income	147.22	33.49	-5.19	-42.99
Net Income to Common	147.22	33.49	-5.19	-42.99
Net Income Growth	339.62%	-	-	-
Shares Outstanding (Basic)	46	45	38	31
Shares Outstanding (Diluted)	46	45	38	31
Shares Change (YoY)	1.61%	20.81%	22.92%	-
EPS (Basic)	3.20	0.74	-0.14	-1.41
EPS (Diluted)	3.20	0.74	-0.14	-1.41
EPS Growth	332.90%	-	-	-
Free Cash Flow	83.63	22.42	10	-35.5
Free Cash Flow Per Share	1.82	0.49	0.27	-1.16
Gross Margin	91.01%	87.10%	90.18%	-
Operating Margin	54.37%	20.96%	-18.15%	-
Profit Margin	51.40%	25.65%	-10.49%	-
Free Cash Flow Margin	29.20%	17.17%	20.22%	-
EBITDA	175.88	43.12	2.58	-41.87
EBITDA Margin	61.41%	33.03%	5.21%	-
D&A For EBITDA	20.15	15.75	11.56	8.8
EBIT	155.73	27.37	-8.98	-50.66
EBIT Margin	54.37%	20.96%	-18.15%	-
Effective Tax Rate	8.82%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.